Cover Image
市場調查報告書

Zecuity(偏頭痛治療藥):市場預測與分析

Zecuity (Migraine) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 301154
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
Zecuity(偏頭痛治療藥):市場預測與分析 Zecuity (Migraine) - Forecast and Market Analysis to 2023
出版日期: 2014年03月31日 內容資訊: 英文 53 Pages
簡介

Zecuity是全球第一個也是唯一一個皮膚貼片,用於提供需要抑制偏頭痛所造成之噁心的緊急治療患者sumatriptan上。Zecuity使用了SmartRelief這個專利技術,透過電泳遞送sumatriptan(透過皮膚遞送藥物用微量電流)。意即只要4小時的投藥時間,電泳中離子化的藥物分子就會穿透皮膚給藥,同時監測皮膚對電泳的抗力。

本報告提供偏頭痛的治療藥之一──Zecuity的全球市場相關分析,提供偏頭痛概要和治療方法,競爭的企業·藥品概要,市場競爭概況,Zecuity的商品資訊(特色·功效·安全性等),全球主要國家的市場販售額預測(今後10年份)等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

  • 本報告概要
  • 相關調查
  • 近日出版的相關調查

第3章 疾病概要

  • 病因與病情
    • 病因
    • 病理生理學
    • 預測
  • 症狀
    • 前驅症狀階段
    • 前兆階段
    • 疼痛的階段
    • 後發症狀的階段

第4章 疾病管理

  • 治療方法概要
    • 急性偏頭痛的治療
    • 偏頭痛的預防療法

第5章 競爭企業的評估

  • 概要
  • 競爭企業的策略性評估

第6章 市場機會及未滿足需求

  • 概要
    • 缺乏具有心血管疾病風險的患者的緊急治療方式
    • 缺乏Triptan療法無效的患者的緊急治療方式
    • 缺乏診斷工具造成的誤診
    • 醫生教育
    • 有效有耐容性的預防療法
  • 未滿足需求的差距分析
    • 具有心血管疾病風險的患者,及Triptan療法無效的患者的緊急治療
    • 有效有耐容性(針對偏頭痛)預防療法
    • 醫生教育
    • 診斷工具

第7章 開發平台評估

  • 概要
  • 臨床實驗中的有潛力的藥劑

第8章 關於Zecuity

  • 概要
  • 功效
  • 安全性
  • 給藥·劑型方法
  • 在臨床方面的潛在性地位
  • 在商業方面的潛在性地位
  • 價格設定和醫療費給付
  • SWOT分析
  • 未來預測

第9章 附錄

圖表一覽

目錄
Product Code: GDHC379DFR

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

Zecuity is the first and only skin patch approved to deliver sumatriptan in patients needing acute treatment to abort their migraines and migraine-related nausea. Zecuity uses a proprietary SmartRelief technology which uses a mild electric current to transport sumatriptan across the skin, a process called iontophoresis. It uses an electric current to pull ionized drug particles through the skin while monitoring the skin's resistance to the transfer of sumatriptan during the four-hour dosing.

Scope

  • Overview of Migraine, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Zecuity including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Zecuity for the US from 2012 to 2023.
  • Sales information covered for the US.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Migraine
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Zecuity performance
  • Obtain sales forecast for Zecuity from 2012-2023 in the US.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
  • 3.2. Symptoms
    • 3.2.1. Premonitory Phase
    • 3.2.2. Aura Phase
    • 3.2.3. Headache Phase
    • 3.2.4. Postdrome Phase

4. Disease Management

  • 4.1. Treatment Overview
    • 4.1.1. Acute Migraine Treatment
    • 4.1.2. Preventive Migraine Treatment

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Opportunity and Unmet Need

  • 6.1. Overview
    • 6.1.1. A Lack of Acute Therapies for Patients with or at Risk of Cardiovascular Disorders
    • 6.1.2. Lack of Acute Therapies for Patients Unresponsive to Triptan Medication
    • 6.1.3. Lack of Diagnostic Tools Causes Misdiagnosis
    • 6.1.4. Physician Education
    • 6.1.5. Effective and Well-Tolerated Prophylactic Therapies
  • 6.2. Unmet Needs Gap Analysis
    • 6.2.1. Acute Therapies for Patients with or at Risk of Cardiovascular Disorders and for Patients Unresponsive to Triptan Medication
    • 6.2.2. Effective and Well-Tolerated (Migraine-Specific) Preventive Therapies
    • 6.2.3. Physician Education
    • 6.2.4. Diagnostic Tools

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising drugs in clinical development

8. Zecuity

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical Positioning
  • 8.6. Potential Commercial Positioning
  • 8.7. Pricing and Reimbursement
  • 8.8. SWOT Analysis
  • 8.9. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Migraine Patients
    • 9.4.2. Percent Drug-treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Generic Erosion
    • 9.4.5. Pricing of Pipeline agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. Survey of Prescribing Physicians
  • 9.7. About the Authors
    • 9.7.1. Author
    • 9.7.2. Reviewer
    • 9.7.3. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Classification of Migraine Subtypes
  • Table 2: Diagnostic Criteria for Migraine with Aura
  • Table 3: Diagnostic Criteria for Migraine without Aura
  • Table 4: Treatment Guidelines for Migraine
  • Table 5: Most Prescribed Drugs for Migraine by Class in the Major Markets, 2013
  • Table 6: Overall Unmet Needs - Current Level of Attainment
  • Table 7: Clinical Unmet Needs - Gap Analysis, 2013
  • Table 8: Migraine - Promising Late-Stage Pipeline, 2013
  • Table 9: Comparison of Therapeutic Classes in Development for Migraine, 2013
  • Table 10: Product Profile - Zecuity
  • Table 11: Zecuity SWOT Analysis, 2013
  • Table 12: Global Sales Forecasts ($m) for Zecuity, 2012-2023
  • Table 13: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Migraine Treatment Algorithm in the 7MM
  • Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Migraine, 2012-2023
Back to Top